why choose us

First received: June 20, 2023

Clinical Trial: Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Urothelial Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Pilot Trial of Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

Brief Summary: This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer.The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.

Read more